Navigation Links
JAMA Oncology Publishes Ambry’s Results Detailing Genes Associated with Hereditary Breast and Ovarian Cancer
Date:8/17/2018

Ambry Genetics Corporation (“Ambry”), a leader in high quality genetic testing, announced their results from the AmbryShare project were published today in JAMA Oncology, identifying new and confirming known hereditary breast and ovarian cancer candidate genes in the largest exome study ever conducted.

Every year hereditary breast cancer affects more than 20,000 women while hereditary ovarian cancer affects more than 6,000 women. Since the discovery of the BRCA1 and BRCA2 genes over 20 years ago, progress in establishing and confirming gene associations with hereditary breast and ovarian cancer has been slow. Major obstacles include limited access to large numbers of relevant samples, sequencing expertise, data sharing and financial resources. The understanding of the genetic component of these cancers has a direct impact on the ability to effectively identify patients susceptible to cancer.

Ambry’s findings were based on a large-scale exome sequencing study of more than 11,400 hereditary breast and ovarian cancer patients from over 1200 clinics and nearly 4000 controls. The study confirmed that the genes PALB2, ATM and CHEK2 significantly increase breast cancer risk and identified the Lynch Syndrome susceptibility gene MSH6 as a candidate gene for breast cancer. In ovarian cancer, both ATM and MSH6 were found to be associated with increased risk along with the well characterized ovarian cancer predisposition genes RAD51C and TP53. Some previously reported associations were not confirmed in the study such as the association of the MRN complex genes and CDKN2A with increased breast or ovarian cancer risk. Likewise, results could not confirm a significant breast cancer association with the ovarian cancer susceptibility genes BRIP, RAD51C, RAD51D, MSH2 and PMS2.

The AmbryShare project highlights the value that large, high resolution, phenotype specific data sets bring to improving patient medical management. In addition to providing evidence for reported but unconfirmed candidate genes, the study was able to identify novel gene associations with breast and ovarian cancer. These results provide further insight into the genomic landscape of hereditary breast and ovarian cancer and will aid in improving the molecular diagnosis of these patients. AmbryShare was conceived to promote and inspire widespread data sharing, and inform comprehensive genetic testing and clinical practice. Learn more about AmbryShare here .

About Ambry
Ambry is both College of American Pathologists (CAP)-accredited and Clinical Laboratory Improvement Amendments (CLIA)-certified. Ambry is a leader in high quality clinical genetic diagnostics and genetics software solutions, combining both to offer the most comprehensive testing menu in the industry. Ambry has established a reputation for sharing data while safeguarding patient privacy, unparalleled service, and responsibly applying new technologies to the clinical molecular diagnostics market. For more information about Ambry, visit ambrygen.com

Media Contact:
Dina Scaglione
Director, Marketing
949.457.4355
dscaglione(at)ambrygen.com

Read the full story at https://www.prweb.com/releases/jama_oncology_publishes_ambrys_results_detailing_genes_associated_with_hereditary_breast_and_ovarian_cancer/prweb15697077.htm.


'/>"/>
Source: PRWeb
Copyright©2018 Vocus, Inc.
All rights reserved


Related biology technology :

1. Immuno-Oncology 360° Summit Confirms Program Line-up for February 7-9, 2018
2. The Trout Group and The Conference Forum Announce Immuno-Oncology 360° Partnership to Fight a Wider Range of Cancers
3. Vortex Biosciences Announces Publication in Nature Precision Oncology Describing the Genomic and Phenotypic Characterization of CTCs from Prostate Cancer Patients
4. Biotech Stocks Under Scanner -- Biostage, Keryx Biopharma, Kite Pharma, and ZIOPHARM Oncology
5. Applied BioMath, LLC announces collaboration with Northern Biologics for semi-mechanistic PK/PD modeling in Oncology
6. Biocom Brings California Oncology Companies to Nations Capitol to Advocate for Innovation in Cancer Treatments and Diagnosis
7. CRO Accelovance Launches Global Initiative to Advance Promising Oncology Therapies
8. BIOARRAY Genetics Inc. Announces the Launch of a Novel Oncology Gene Panel
9. Nektar Therapeutics Presents New Preclinical Data for its Immuno-Oncology Programs at the American Association for Cancer Research (AACR) Annual Meeting
10. BERG Announces BPM 31510 Data Presentations at 2017 AACR in Immuno-Oncology, Glioblastoma Mutiforme, Pancreatic Cancers and Novel Prostate Cancer Biomarker Panel
11. Applied BioMath, LLC announces collaboration with Zymeworks Inc. for Clinical Trial Support in Oncology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/29/2018)... ... 2018 , ... RAGS, today announced the closing of a $1.5 million Second ... existing investor and board member Jeremy Andrus, CEO of Traeger Grills, as well as ... enable the company to accelerate its growth and expand the product line. RAGS has ...
(Date:11/27/2018)... ... 27, 2018 , ... New patients in need of a dental crown ... with or without a referral. Dr. Myers has many years of experience improving patient ... bridges and custom crowns. , As a dedicated cosmetic dentist , Dr. ...
(Date:11/20/2018)... VANCOUVER, British Columbia (PRWEB) , ... November 19, ... ... Repositories (ISBER) is pleased to announce the release of the Chinese translation of ... released in January 2018, is a practice-changing publication aimed at advancing the science ...
(Date:11/20/2018)... ... ... Each year Forbes receives thousands of nominations for candidates wishing to be ... under 30 years of age. The Forbes 30 Under 30 list showcases the top ... Capital and Science. , In 2017, Visikol CEO Dr. Michael Johnson was named ...
Breaking Biology Technology:
(Date:12/5/2018)... ... December 04, 2018 , ... ... oligo synthesizer, the Dr. Oligo 192c, built on Biolytic’s Molecule Synthesis Platform. ... have allowed them to become the world’s fastest in oligonucleotide synthesis, the 192c ...
(Date:11/29/2018)... Pa. (PRWEB) , ... November 29, 2018 , ... ... investment in Semba Biosciences with the intention of acquiring full ownership. The transaction ... Participation Agreement was executed on November 14, 2018. “We are extremely pleased to ...
(Date:11/27/2018)... ... 26, 2018 , ... PulseEd™ uses researched technology, published in the Journal ... blood flow to the penis. Regular and unimpeded blood flow to the blood vessels ... erectile function. The recorded results of SWT (sound wave therapy), indicated that almost 80% ...
Breaking Biology News(10 mins):